ATCC today announced the launch of a new authentication service that will allow researchers to easily confirm the identity of mouse cell lines. Developed in partnership with the National Institutes for Standards and Technology (NIST), the service demonstrates ATCC’s continued leadership in developing global biological standards.
The Bioprocessing Network Australia (BPN) has selected Probiotics Australia as the site for the next QLD satellite event now that Probiotics Australia has been launched and started production.
Probiotics Australia is a purpose built, cutting-edge bio-manufacturing facility, located in Ormeau, Queensland, it was officially opened in May 2019. The TGA cGMP licensed facility houses research, development and production laboratories in addition to sizable warehousing and offices. The site is also certified by Australian Certified Organic, HACCP approved, and FDA registered.
ATCC Pledges to Advance Authentication
Are you willing to stake the integrity of your research on potentially unreliable starting materials? Your incredible advancements are too important to risk.
In ATCC's latest short documentary film, “Next-Generation Biological Models: Revolutionizing Cancer Research,” they focus on the Human Cancer Models Initiative (HCMI), a groundbreaking international research collaboration to transform cancer research and therapeutic development.
Recently, Tocris announced the release of some new Chemogenetic tools for Neuroscience research - PSEMs, pharmacologically selective effector molecules.
We are very pleased to announce that Polyplus-transfection® SA, has trusted In Vitro Technologies as their new exclusive distributor in Australia and New Zealand.
Located close to the University of Strasbourg in France, Polyplus-transfection® SA is a biotechnology company that develops and sells innovative, high efficiency transfection reagents for the delivery of nucleic acids in research, bioproduction and therapeutics.
We are very pleased to announce that Terumo BCT has appointed In Vitro Technologies as their new distributor in Australia and New Zealand effective 1 June 2018, supporting the Cell Therapy Technologies range of products.
ATCC's toxicological tools can also be used to identify responses to environmental insults or to screen pharmaceutical compounds. These cells are applicable for bench work and large-scale screening and are fully characterized and functionally tested.
ATCC has updated the White Paper Synthetic Nucleic Acids for the Development and Evaluation of In Vitro Diagnostic Devices Designed to Detect Dengue, Chikungunya, and Zika White Paper.
To support Australian and New Zealand research in the fight against cancer, In Vitro Technologies offered 5 Travel Grants to Australian and New Zealand researchers to attend the Eradicate Cancer Conference in Melbourne in March 2018. And the winners are...
